Patents Assigned to Sphingotec GmbH
  • Publication number: 20180128838
    Abstract: The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (CKD) using Pro-Enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases. Subject matter of the invention is also a method of predicting the worsening or improvement of kidney function or dysfunction in healthy and diseased individuals.
    Type: Application
    Filed: April 21, 2016
    Publication date: May 10, 2018
    Applicant: sphingotec GmbH
    Inventors: Andreas BERGMANN, Olle MELANDER
  • Publication number: 20170307618
    Abstract: Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising: determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of Pro-Enkephalin or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 26, 2017
    Applicant: SPHINGOTEC GMBH
    Inventors: Andreas BERGMANN, Olle MELANDER
  • Publication number: 20170261522
    Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.
    Type: Application
    Filed: May 9, 2017
    Publication date: September 14, 2017
    Applicant: SPHINGOTEC GMBH
    Inventor: Andreas BERGMANN
  • Publication number: 20170234889
    Abstract: A method of determining whether a subject has a vascular risk that can be reduced by blood pressure lowering therapy with antihypertensive drugs (e.g. Angiotensin converting enzyme inhibitor (ACE inhibitor), Angiotensin Receptor Blocker (ARB), Beta-Adrenoreceptor Blocker (Beta-blocker) and/or statins) by determining the level of hGH, and/or its isoforms in a blood sample of said subject and comparing the determined level of hGH, and/or its isoforms in said blood sample with a pre-determined threshold.
    Type: Application
    Filed: October 1, 2015
    Publication date: August 17, 2017
    Applicant: Sphingotec GmbH
    Inventors: Andreas BERGMANN, Olle MELANDER, Leong NG
  • Patent number: 9702876
    Abstract: Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising: determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of Pro-Enkephalin or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 11, 2017
    Assignee: SPHINGOTEC GMBH
    Inventors: Andreas Bergmann, Olle Melander
  • Patent number: 9664695
    Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: May 30, 2017
    Assignee: Sphingotec GmbH
    Inventor: Andreas Bergmann
  • Publication number: 20170052203
    Abstract: Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ. ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. Subject of the present invention are further assays and calibration methods.
    Type: Application
    Filed: November 7, 2016
    Publication date: February 23, 2017
    Applicant: SPHINGOTEC GMBH
    Inventor: Andreas BERGMANN
  • Publication number: 20170010286
    Abstract: Subject matter of the present invention is an in vitro method for identifying a subject in need of administration of fluid resuscitation or a vasopressor comprising the following steps: Determining the level of proADM and/or fragments thereof having at least 6 amino acids in a bodily fluid of said subject Correlating said level with the need of said patient for fluid resuscitation or administration of a vasopressor wherein said patient is identified as having such a need if the level of proADM and/or fragments thereof having at least 6 amino acids in the bodily fluid of said subject is above a threshold.
    Type: Application
    Filed: March 19, 2014
    Publication date: January 12, 2017
    Applicant: SphingoTec GmbH
    Inventor: Andreas BERGMANN
  • Patent number: 9535060
    Abstract: Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. Subject of the present invention are further assays and calibration methods.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: January 3, 2017
    Assignee: SPHINGOTEC GMBH
    Inventor: Andreas Bergmann
  • Publication number: 20160252526
    Abstract: Disclosed is a method for predicting the risk of getting a major adverse cardiac event or death in a subject that has suffered an acute myocardial infarction containing determining the level of Protachykinin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from the subject; and correlating the level of Protachykininor fragments thereof with the a risk for getting a major adverse cardiac event or death, wherein an elevated level is predictive for an enhanced risk of getting a major adverse cardiac event or death.
    Type: Application
    Filed: September 30, 2014
    Publication date: September 1, 2016
    Applicant: sphingotec GmbH
    Inventors: Andreas BERGMANN, Leong NG
  • Publication number: 20160097781
    Abstract: Subject matter of the present invention is a method for stratifying a female subject for hormone replacement therapy wherein the level of Pro-Neurotensin or fragments thereof is determined and the level of Pro-Enkephalin or fragments thereof is determined.
    Type: Application
    Filed: October 1, 2015
    Publication date: April 7, 2016
    Applicant: SPHINGOTEC GMBH
    Inventors: Andreas BERGMANN, Olle MELANDER
  • Publication number: 20150346222
    Abstract: Subject matter of the present invention is a method for predicting the cardiovascular risk or the total mortality risk in a subject comprising: determining the fasting level of growth hormone (hGH), and/or its isoforms in a bodily fluid obtained from said subject; and correlating said fasting level of growth hormone (hGH), and/or its isoforms with a cardiovascular risk or the total mortality risk, wherein an enhanced level is predictive for an enhanced risk.
    Type: Application
    Filed: January 7, 2014
    Publication date: December 3, 2015
    Applicant: SPHINGOTEC GMBH
    Inventor: Andreas BERGMANN
  • Publication number: 20150346207
    Abstract: Subject matter of the present invention is a method for predicting the risk of getting cancer in a subject that does not suffer from cancer or alternatively diagnosing cancer in a subject comprising: determining the level of Pro-Tachykinin, its splice variants or fragments thereof including Substance P and Neurokinin of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Tachykinin, its splice variants or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.
    Type: Application
    Filed: January 7, 2014
    Publication date: December 3, 2015
    Applicant: SphingoTec GmbH
    Inventor: Andreas BERGMANN
  • Patent number: 9188591
    Abstract: The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other biological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of pain, neurological, endocrinological, cerebral, muscular, local, systemic, chronic, inflammatory diseases, infectious diseases comprising bacterial and viral infections, meningitis, sepsis, Crohn's disease, colitis ulcerosa, sickle cell anemia, ischemia, amyotrophic lateral sclerosis, arthritis comprising rheumatoid arthritis, bronchitis, hyperalgesia, asthma, intoxication comprising bacterial intoxication, immunological disorders, poly/-trauma comprising cranio-cerebral trauma, tumors/cancer, stroke, stress, atopis dermatitis, HIV, Huntington's disease, burns, schizophrenia, Hirschsprung's disease, allergies, familial dysautononmia (Riley Day syndrome), he
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: November 17, 2015
    Assignee: SPHINGOTEC GMBH
    Inventors: Andreas Bergmann, Andrea Ernst
  • Publication number: 20150268240
    Abstract: Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising: determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of Pro-Enkephalin or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.
    Type: Application
    Filed: October 1, 2013
    Publication date: September 24, 2015
    Applicant: SPHINGOTEC GMBH
    Inventors: Andreas Bergmann, Olle Melander
  • Publication number: 20150260732
    Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.
    Type: Application
    Filed: October 1, 2013
    Publication date: September 17, 2015
    Applicant: SPHINGOTEC GMBH
    Inventor: Andreas Bergmann
  • Patent number: 8916388
    Abstract: In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: December 23, 2014
    Assignee: Sphingotec GmbH
    Inventors: Andreas Bergmann, Andrea Ernst, Harald Hampel
  • Publication number: 20140322824
    Abstract: Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. Subject of the present invention are further assays and calibration methods.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 30, 2014
    Applicant: SPHINGOTEC GMBH
    Inventor: Andreas Bergmann
  • Patent number: 8637256
    Abstract: The invention relates to an immunodiagnostic method for determining the release of neurotensin into the circulation of mammals based on the selective determination of an immunoreactivity of the N-terminal portion of a mammal proneurotensin (PNT immunoreactivity) in a serum or plasma sample of a mammal; this immunoreactivity is not neurotensin or neuromedin immunoreactivity.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: January 28, 2014
    Assignee: Sphingotec GmbH
    Inventor: Andrea Ernst
  • Publication number: 20120231475
    Abstract: The invention relates to an immunodiagnostic determination method for determining the release of neurotensin into the circulation of mammals during which an immunoreactivity of the N-terminal portion of a mammal proneurotensin (PNT immunoreactivity) is selectively determined in a serum sample or plasma sample of a test mammal, this immunoreactivity not being a neurotensin or neuromedin immunoreactivity.
    Type: Application
    Filed: February 22, 2012
    Publication date: September 13, 2012
    Applicant: SPHINGOTEC GMBH
    Inventor: Andrea ERNST